Germany-based Sandoz has launched its generic Icatibant injection pre-filled syringe in the United States, it was reported on Thursday.
The product is intended to treat acute attacks of rare disease hereditary angioedema in adults 18 years and older. The company is offering the product to patients in the United States immediately. It has signed a US commercialisation contract with Slayback Pharma for this medicine, which is a generic equivalent to Takeda's Firazyr (icatibant injection).
Keren Haruvi, president, Sandoz Inc, said, 'We are eager to see the positive effects of making generic Icatibant available immediately to people living with this painful and disabling rare disease. This collaboration aligns with our goal to build our injectables portfolio and provide US patients access to affordable generic medicines that work the same as brand-name products.'
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US